前往化源商城

品牌现货直购
供应商:我要出现这里


查看所有供应商和价格请点击:

525-66-6生产厂家

525-66-6价格

525-66-6

525-66-6结构式
525-66-6结构式
  • 常用中文名:心得安(普萘洛尔)
  • 常用英文名:propranolol
  • CAS号:525-66-6
  • 分子式:C16H21NO2
  • 分子量:259.34300
  • 相关类别: 原料药 循环系统用药 抗心律失常药
  • 发布时间:2018-02-04 08:00:00
  • 更新时间:2024-01-02 19:53:39
  • Propranolol 普萘洛尔是一种非心脏选择性 β 受体阻滞剂 β-blocker。Propranolol 具有膜稳定性质,但不具有内在的拟交感神经活性。Propranolol 用于控制高血压,嗜铬细胞瘤,心肌梗塞,心律失常,心绞痛和肥厚性心肌病。
  • 普萘洛尔(心得安)与去甲肾上腺素能神经递质或拟肾上腺素因药物竞争β受体,从而抑制去甲肾上腺素能经神支配器官的β效应。
    ⒈心血管 对心脏β1受体阻断作用较强,可使心率减慢,心肌收缩力减弱;能降低心肌自律性,延长有效不应期(effective refractory period,ERP),减慢传导,使心输出量减少,心肌耗氧降低,血压稍降低。心得安对心脏抑制作用强度与心脏交感神经的张力大小有关,如运动、病理状态时交感神经的张力增高,心得安对心脏的抑制作用较强,对正常人休息时心脏作用较弱。心得安可反射性引起外周阻力增加,使内脏(肝、肾等)器官血流减少,冠脉流量亦降低。
    ⒉支气管平滑肌阻断β2受体,可使支气管平滑肌收缩,对支气管哮喘患者可诱发或加重急性发作。
    ⒊其他 ①内在拟交感神经活动性,有些β受体阻断药物尚有一定程度的兴奋β受体的性能,这种性能是内在拟交感活动性所引起的β受体兴奋效应,往往被β受体阻断效应所掩盖,但可以对抗或减弱β型应用的效果;②膜定作用,有些β受体阻断剂尚有局部麻醉和直接抑制心脏作用(奎尼丁样作用)。这两种作用都是由于稳定细胞膜,使神经纤维或心肌细胞膜对阳离子的通透性降低所致,故统称为膜定作用。

化源商城直购

中文名 心得安(普萘洛尔)
英文名 propranolol
中文别名 1-异丙基氨基-3-(萘-1-氧基)丙-2-醇
心得安
萘心安
恩得来
萘氧丙醇胺
普萘洛尔
英文别名 Disoprivan
Propranolol
Fresofol
2,6-diisopropylphenol
2-Propanol,1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-
Propofolum
Disoprofol
Diprivan
2-hydroxy-1,3-diisopropylbenzene
propofol
2,6-i-Pr2-C6H3-OH
Diisopropylphenol
描述 Propranolol 普萘洛尔是一种非心脏选择性 β 受体阻滞剂 β-blocker。Propranolol 具有膜稳定性质,但不具有内在的拟交感神经活性。Propranolol 用于控制高血压,嗜铬细胞瘤,心肌梗塞,心律失常,心绞痛和肥厚性心肌病。
相关类别
参考文献

[1]. Al-Majed AA, et al. Propranolol. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.

密度 1.093 g/cm3
沸点 434.9ºC at 760 mmHg
熔点 163-164ºC
分子式 C16H21NO2
分子量 259.34300
闪点 216.8ºC
精确质量 259.15700
PSA 41.49000
LogP 2.96840
外观性状 白色,无气味的结晶粉末
折射率 1.5500 (estimate)
储存条件 室温

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UB7500000
CHEMICAL NAME :
2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-
CAS REGISTRY NUMBER :
525-66-6
LAST UPDATED :
199709
DATA ITEMS CITED :
29
MOLECULAR FORMULA :
C16-H21-N-O2
MOLECULAR WEIGHT :
259.38
WISWESSER LINE NOTATION :
L66J BO1YQ1MY1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
708 mg/kg/39W-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3200 ug/kg/2D-I
TOXIC EFFECTS :
Endocrine - hypoglycemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
2300 ug/kg/D
TOXIC EFFECTS :
Behavioral - hallucinations, distorted perceptions
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
800 ug/kg/12H
TOXIC EFFECTS :
Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - acute pulmonary edema
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
400 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Cardiac - arrhythmias (including changes in conduction)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
8343 mg/kg/4Y-I
TOXIC EFFECTS :
Endocrine - evidence of thyroid hyperfunction
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human
DOSE/DURATION :
71 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
22857 ug/kg/40D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Ear) - change in acuity
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
660 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
23 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
289 mg/kg
TOXIC EFFECTS :
Autonomic Nervous System - beta-adrenergic blockage
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
42 mg/kg
TOXIC EFFECTS :
Autonomic Nervous System - beta-adrenergic blockage
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
28100 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - mydriasis (pupillary dilation) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
26 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
7 gm/kg/35D-C
TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - other changes Blood - changes in spleen
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1096 mg/kg
SEX/DURATION :
female 1-40 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) Reproductive - Effects on Newborn - Apgar score (human only)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Multiple routes
DOSE :
932 mg/kg
SEX/DURATION :
female 4-40 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
966 mg/kg
SEX/DURATION :
male 6 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
650 mg/kg
SEX/DURATION :
female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
325 mg/kg
SEX/DURATION :
female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
1 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
300 mg/kg
SEX/DURATION :
female 10-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death

MUTATION DATA

TEST SYSTEM :
Rodent - mouse
DOSE/DURATION :
74500 ug/kg
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 173,207,1986 *** REVIEWS *** TOXICOLOGY REVIEW FAATDF Fundamental and Applied Toxicology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1981- Volume(issue)/page/year: 6,395,1986 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4181 No. of Facilities: 17 (estimated) No. of Industries: 2 No. of Occupations: 7 No. of Employees: 1785 (estimated) No. of Female Employees: 355 (estimated)

海关编码 2922210000
海关编码 2922509090
中文概述 2922509090. 其他氨基醇酚、氨基酸酚及其他含氧基氨基化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:AB. 最惠国关税:6.5%. 普通关税:30.0%
申报要素 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装
监管条件 A.入境货物通关单 B.出境货物通关单
检验检疫 R.进口食品卫生监督检验 S.出口食品卫生监督检验
Summary 2922509090. other amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%